Changchun Genescience Pharmaceuticals Co. Ltd. has discovered new ubiquitin carboxyl-terminal hydrolase 30 (USP30) inhibitors potentially useful for the treatment of mitochondrial and Parkinson’s disease.
Chomix Biotech (Nanjing) Co. Ltd. has patented new irreversible fibroblast activation protein-α (FAPα) inhibitors potentially useful for the diagnosis or treatment of rheumatoid arthritis, atherosclerosis, cancer, myocardial infarction, kidney fibrosis, pulmonary and hepatic fibrosis, and among others.
Synnovation Therapeutics Inc. has identified new heterocyclic poly(ADP-ribose) glycohydrolase (PARG) inhibitors described as useful for the treatment of cancer.
Bristol Myers Squibb Co. (BMS) has disclosed new 1H-benzo[d]imidazole derivatives acting as calcium/calmodulin-dependent protein kinase type II (CAMK2) inhibitors potentially useful for the treatment of anxiety disorders, asthma, cardiomyopathy, diabetes, fibrosis, heart failure, hypertension and allergy, among others.
China Pharmaceutical University and the Chongqing Innovation Institute, China Pharmaceutical University have synthesized new asiaticoside saponin compounds reported to be useful for the treatment of inflammation, cancer and ulcerative colitis.
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s disease.
RSS